Mueller L, Gallagher R M, Ciervo C A
Department of Family Practice, University Headache Center, Moorestown, NJ 08057, USA.
Headache. 1996 May;36(5):329-31. doi: 10.1046/j.1526-4610.1996.3605329.x.
Sumatriptan, a 5-hydroxytryptamine1, (5-HT1) receptor agonist is an effective abortive agent for migraine headaches. A common side effect in 3% to 7.9% of patients is chest pain. Although most cases of chest pain are not thought to be of cardiac origin, its mechanism is not entirely understood. Rare examples of electrocardiogram changes consistent with transient ischemia have been reported. Isolated instances of angina, arrhythmia, myocardial infarction, and death have been temporally associated with sumatriptan administration. In most cases, it is unclear whether underlying cardiovascular disease existed or contributed to this adverse event. We report the history of a 56-year-old female patient with migraine who experienced a myocardial infarction shortly after using sumatriptan, despite having had a normal cardiovascular evaluation. As she had a normal cardiac catheterization after the event, we find it probable that sumatriptan induced coronary vasospasm and myocardial infarction.
舒马曲坦是一种5-羟色胺1（5-HT1）受体激动剂，是治疗偏头痛的一种有效终止药物。3%至7.9%的患者常见的副作用是胸痛。虽然大多数胸痛病例被认为并非心脏源性，但其机制尚不完全清楚。已有报告罕见的与短暂性缺血一致的心电图改变病例。也曾有孤立的心绞痛、心律失常、心肌梗死和死亡病例在时间上与使用舒马曲坦相关。在大多数情况下，尚不清楚是否存在潜在的心血管疾病或其是否导致了这一不良事件。我们报告一名56岁偏头痛女性患者的病史，她在使用舒马曲坦后不久发生了心肌梗死，尽管其心血管评估结果正常。由于事件发生后她的心脏导管检查结果正常，我们认为很可能是舒马曲坦诱发了冠状动脉痉挛和心肌梗死。
